Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
I'm PortAI, I can summarize articles.
Novartis AG has completed its acquisition of Regulus Therapeutics for $1.7 billion, confirming the deal on June 23. Following the acquisition, Regulus shares have ceased trading on NASDAQ, and it is now a fully owned subsidiary of Novartis. This move positions Novartis as one of the top European stocks to invest in.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments